Every 10-Q that CAMP4 Therapeutics Corporation (CAMP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CAMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAMP filings page.
CAMP4 Therapeutics Corporation reported for the quarter ended June 30, 2026 that it remains a clinical-stage company focused on RNA-targeting therapeutics, with lead candidate CMP-002 for SYNGAP1-related disorder. Research and collaboration revenue was $1.8 million for the quarter and $3.1 million year-to-date, largely from its collaboration with GSK.
Operating expenses stayed high as development advanced, with R&D of $20.98 million and G&A of $8.55 million for the six-month period. A large non-cash $27.12 million loss from remeasurement of a derivative tranche liability tied to a private placement drove the six‑month net loss to $51.86 million and turned stockholders’ equity into a small deficit.
Cash and cash equivalents were $86.40 million at June 30, 2026, with total cash, cash equivalents and restricted cash of $88.02 million and negative operating cash flow of $23.67 million for the first half. Management states that existing cash plus $46.9 million of proceeds received in August 2026 from the second closing of the private placement are expected to fund operations through the end of 2028. Subsequent to quarter-end, regulatory clearances in Australia and Argentina allow initiation of a Phase 1/2 trial of CMP‑002.
CAMP4 Therapeutics Corporation reports first-quarter 2026 results, showing higher collaboration revenue but a wider net loss as it advances its RNA-targeting pipeline. Revenue from research and collaboration grew to $1.3 million, mainly from its agreement with GSK. Research and development expenses were $10.2 million and general and administrative costs $4.2 million, keeping total operating expenses broadly flat versus last year.
The company recorded a non-cash $6.2 million loss from remeasuring its derivative tranche liability linked to a potential second private-placement closing, driving net loss to $18.3 million and basic and diluted net loss per share to $0.32. Operating cash outflow was $11.0 million.
CAMP4 ended the quarter with $99.2 million in cash and cash equivalents and $30.9 million in stockholders’ equity, and believes existing cash will fund operations into 2028. The company is preparing a global Phase 1/2 trial of lead candidate CMP-002 for SYNGAP1-related disorder and continues to leverage its RAP Platform and a $17.5 million GSK collaboration to support future programs.
CAMP4 Therapeutics reported a Q3 net loss of $15.1 million as it advances RNA‑targeting programs and collaboration work. Revenue was $0.8 million in the quarter and $3.15 million year‑to‑date, driven by the BioMarin agreement and a Fulcrum milestone earlier in the year.
Cash and cash equivalents were $75.3 million at September 30, 2025, and management states this is sufficient to fund operations for at least the next twelve months. During September, the company completed an initial private placement closing, issuing 26,717,414 common shares and 6,003,758 pre‑funded warrants for $46.7 million in net cash proceeds. A related derivative tranche liability of $16.7 million was recorded, reflecting investors’ rights to a potential second closing subject to specified triggers.
R&D expense was $9.4 million in Q3 as CAMP4 progressed CMP‑002 toward GLP tox for SYNGAP1‑related disorders and paused new investment in CMP‑001 for urea cycle disorders while seeking partners. Shares outstanding were 46,880,185 at quarter‑end; 46,881,134 were outstanding as of November 3, 2025.
CAMP4 Therapeutics is a clinical-stage company developing RNA-targeting therapies using its RAP Platform. The company reported $39.1 million in cash and cash equivalents and $33.8 million of working capital as of June 30, 2025, after raising aggregate net IPO proceeds of $72.4 million (including partial exercise proceeds). CAMP4 recorded a $25.0 million net loss for the six months ended June 30, 2025 (same as prior year) and has an accumulated deficit of $236.8 million. Management estimates existing cash will fund operations into the second quarter of 2026 but concludes there is substantial doubt about the company’s ability to continue as a going concern without additional financing. CAMP4 recognized collaboration revenue including a $0.6 million Fulcrum milestone and $0.9 million and $1.8 million of BioMarin collaboration revenue for the three- and six-month periods of 2025, respectively. The company presented encouraging preclinical SYNGAP program data in May 2025 and plans GLP toxicology studies in Q3 2025 to enable a clinical filing.